"Hyperlipidemias" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions with excess LIPIDS in the blood.
| Descriptor ID |
D006949
|
| MeSH Number(s) |
C18.452.584.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hyperlipidemias".
Below are MeSH descriptors whose meaning is more specific than "Hyperlipidemias".
This graph shows the total number of publications written about "Hyperlipidemias" by people in this website by year, and whether "Hyperlipidemias" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 2 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 1 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperlipidemias" by people in Profiles.
-
Ogungbe O, Akil L, Ahmad HA. Exploring Unconventional Risk-Factors for Cardiovascular Diseases: Has Opioid Therapy Been Overlooked? Int J Environ Res Public Health. 2019 07 18; 16(14).
-
Zhao X, Chen X, Zhang Y, George J, Cobbs A, Wang G, Li L, Emmett N. Kidney Injury Molecule-1 Is Upregulated in Renal Lipotoxicity and Mediates Palmitate-Induced Tubular Cell Injury and Inflammatory Response. Int J Mol Sci. 2019 Jul 11; 20(14).
-
El-Zailik A, Cheung LK, Wang Y, Sherman V, Chow DS. Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery. J Pharm Biomed Anal. 2019 Feb 05; 164:258-267.
-
White CM, Weeda ER, Nguyen E. Should an LDL-Cholesterol Target-Based Approach Be Readopted? Ann Pharmacother. 2018 02; 52(2):175-184.
-
Wong LL, Reyes RJ, Kwee SA, Hernandez BY, Kalathil SC, Tsai NC. Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world? Clin Mol Hepatol. 2017 Sep; 23(3):239-248.
-
Smith L, Mosley J, Yates J, Caswell L. The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy. J Pharm Pharm Sci. 2016; 19(1):137-46.
-
Ko J, Delafield R, Davis J, Mau MK. Characteristics of patients with type 2 diabetes mellitus in two rural, medically underserved communities. Hawaii J Med Public Health. 2013 Jun; 72(6):191-6.
-
Hsia SH, Desnoyers ML, Lee ML. Differences in cholesterol management among states in relation to health insurance and race/ethnicity across the United States. J Clin Lipidol. 2013 Nov-Dec; 7(6):675-82.
-
Davis J, Juarez D, Hodges K. Relationship of ethnicity and body mass index with the development of hypertension and hyperlipidemia. Ethn Dis. 2013; 23(1):65-70.
-
Ravella K, Yang H, Gangula PR. Impairment of gastric nitrergic and NRF2 system in apolipoprotein E knockout mice. Dig Dis Sci. 2012 Jun; 57(6):1504-9.